0001562180-24-000035.txt : 20240102 0001562180-24-000035.hdr.sgml : 20240102 20240102174146 ACCESSION NUMBER: 0001562180-24-000035 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231228 FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lurker Nancy CENTRAL INDEX KEY: 0001450485 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 24503691 MAIL ADDRESS: STREET 1: PDI, INC. STREET 2: 1 ROUTE 17 SOUTH CITY: SADDLE RIVER STATE: NJ ZIP: 07458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2023-12-28 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001450485 Lurker Nancy C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 true true false false Executive Vice Chair false Stock Option (Right to Buy) 13.13 2023-12-28 4 G false 31164.00 0.00 D 2031-02-09 Common Stock 31164.00 62330.00 D Stock Option (Right to Buy) 13.13 2023-12-28 4 G false 31164.00 0.00 A 2031-02-09 Common Stock 31164.00 151370.00 I By Family Trust Stock Option (Right to Buy) 12.90 2023-12-28 4 G false 10906.00 0.00 D 2030-02-28 Common Stock 10906.00 4674.00 D Stock Option (Right to Buy) 12.90 2023-12-28 4 G false 10906.00 0.00 A 2030-02-28 Common Stock 10906.00 70126.00 I By Family Trust Stock Option (Right to Buy) 10.13 2023-12-28 4 G false 35000.00 0.00 D 2032-02-09 Common Stock 35000.00 130000.00 D Stock Option (Right to Buy) 10.13 2023-12-28 4 G false 35000.00 0.00 A 2032-02-09 Common Stock 35000.00 110000.00 I By Family Trust On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024. On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023. The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. /s/ Ron Honig, Attorney-in-Fact 2024-01-02